Literature DB >> 2550248

Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes.

M J Schleuning1, A Duggan, G H Reem.   

Abstract

This study was designed to determine the effect of the phenothiazine chlorpromazine (CPZ) on the activation of human thymocytes. We provide evidence that CPZ inhibits the accumulation of mRNA specific for the lymphokines, interleukin 2, interferon-gamma, tumor necrosis factor alpha and the proto-oncogene c-myc; by contrast, the accumulation of mRNA specific for the alpha chain of the interleukin 2 receptor and the subsequent early expression of Tac antigen on the cell surface is not inhibited by CPZ. The inhibition of the expression of lymphokine-specific mRNA results in a decrease in interferon-gamma synthesis and in inhibition of thymocyte proliferation as determined by the incorporation of [3H]thymidine. In addition, we show that activation of protein kinase C (PKC) in human thymocytes by 12-O-tetradecanoyl phorbol 13-acetate (TPA) causes the phosphorylation of a protein of a molecular mass of approximately 75 kDa. The function of this protein is as yet not defined, but it is possible that it plays a role in the transduction of the signals to the nucleus which in turn elicit the expression of the genes coding for c-myc and for the lymphokines required for thymocyte activation. We also demonstrate that CPZ, like the immunosuppressant drug cyclosporin A does not inhibit the phosphorylation of the 75-kDa protein which is induced by the activation of PKC by TPA and does not affect phosphoinositide breakdown, indicating that it exerts its effect at a site distal to the activation of PKC. These observations demonstrate that CPZ has an immunoregulatory function in addition to its psychotropic activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550248     DOI: 10.1002/eji.1830190822

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives.

Authors:  M Schleuning; V Brumme; W Wilmanns
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-07       Impact factor: 3.000

2.  Auditory and visual hallucinations after influenza vaccine: a case report.

Authors:  Stefania Antoniazzi; Carla Carnovale; Aurelio Sessa; Marta Gentili; Marco Matacena; Maurizia Punginelli; Emilio Clementi; Sonia Radice
Journal:  Ther Adv Vaccines       Date:  2016-10-21

3.  Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in mice.

Authors:  Adarsh Gandhi; Tao Guo; Pranav Shah; Bhagavatula Moorthy; Romi Ghose
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-11       Impact factor: 4.219

4.  The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-10 in human volunteers.

Authors:  M W Bleeker; M G Netea; B J Kullberg; J Van der Ven-Jongekrijg; J W Van der Meer
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

5.  Modulators of the activation of the proteasome by PA28 (11S reg).

Authors:  S Wilk; W E Chen; R P Magnusson
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

Review 6.  Tumor necrosis factor: an update on basic research and clinical applications.

Authors:  M Schleuning; R Munker
Journal:  Klin Wochenschr       Date:  1990-09-03

7.  Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.

Authors:  N Müller; M Empl; M Riedel; M Schwarz; M Ackenheil
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

8.  Inhibition by SK&F 96365 of Ca2+ current, IL-2 production and activation in T lymphocytes.

Authors:  S C Chung; T V McDonald; P Gardner
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock.

Authors:  M Gadina; R Bertini; M Mengozzi; M Zandalasini; A Mantovani; P Ghezzi
Journal:  J Exp Med       Date:  1991-06-01       Impact factor: 14.307

10.  Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics.

Authors:  Adonis Sfera; Sabine Hazan; Jonathan J Anton; Dan O Sfera; Christina V Andronescu; Sarvin Sasannia; Leah Rahman; Zisis Kozlakidis
Journal:  Front Pharmacol       Date:  2022-09-09       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.